MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412529 | Name: Cefozopran free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefozopran, also known as SCE-2787 and Firstcin, is a cell wall biosynthesis inhibitor with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. SCE-2787 inhibited 50% of tested isolates of the family Enterobacteriaceae at < or = 0.25 micrograms/ml. SCE-2787 was equally active as or more active than ceftazidime and ceftriaxone against members of the Enterobacteriaceae, except Proteus vulgaris. SCE-2787 inhibited beta-hemolytic streptococci at < or = 0.12 micrograms/mL.

Chemical Structure

Cefozopran free base
CAS#113359-04-9 (free base)

Theoretical Analysis

MedKoo Cat#: 412529

Name: Cefozopran free base

CAS#: 113359-04-9 (free base)

Chemical Formula: C19H17N9O5S2

Exact Mass: 515.0794

Molecular Weight: 515.52

Elemental Analysis: C, 44.27; H, 3.32; N, 24.45; O, 15.52; S, 12.44

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
113359-04-9 (free base) 113981-44-5 (HCl)
Synonym
Cefozopran free base; CZOP; SCE2787; SCE-2787; SCE 2787;
IUPAC/Chemical Name
(6R,7R)-3-((1H-imidazo[1,2-b]pyridazin-4-ium-1-yl)methyl)-7-((Z)-2-(5-amino-1,2,4-thiadiazolidin-3-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
InChi Key
QDUIJCOKQCCXQY-WHJQOFBOSA-N
InChi Code
InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1
SMILES Code
CO/N=C(c1nc(N)sn1)\C(N[C@H]2[C@H]3SCC(C[n+](cc4)c5n4nccc5)=C(C([O-])=O)N3C2=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
SCE-2787 is a new cephalosporin having a condensed azolium moiety in the 3 position and an aminothiadiazolyl group in the 7 beta side chain. SCE-2787 was more active than ceftazidime and E1040 and was as active as flomoxef and cefpirome, with MICs for 90% of strains tested (MIC90s) being 1.56 micrograms/ml or less. SCE-2787 was also active against Pseudomonas aeruginosa, for which the MIC90 was 6.25 micrograms/ml, which was lower than that of cefpirome and comparable to that of ceftazidime. SCE-2787 was marginally active against methicillin-resistant strains of staphylococci and Enterococcus faecalis, although its MIC90s were the lowest among those of the antibiotics tested. The activities of SCE-2787 against Streptococcus species, most members of the family Enterobacteriaceae, and Haemophilus influenzae exceeded those of ceftazidime and flomoxef and were comparable to those of cefpirome. Furthermore, MIC90s of SCE-2787 were significantly lower than those of ceftazidime for ceftazidime-resistant isolates of Citrobacter freundii and Enterobacter cloacae. SCE-2787 was resistant to hydrolysis by various types of beta-lactamases, including the Bush group 1 beta-lactamases, and had low affinities for these enzymes, with Km or Ki values of greater than 100 microM. The in vitro activity of SCE-2787 was reflected in its efficacy in mouse protection tests. Thus, SCE-2787 appears to be a promising cephalosporin that should be further evaluated in clinical trials.

Preparing Stock Solutions

The following data is based on the product molecular weight 515.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kobayashi R, Sano H, Matsushima S, Hori D, Yanagi M, Suzuki D. Analysis of bacteremia at first-line antibiotic treatment for febrile neutropenia in children and adolescents: A retrospective, single-center analysis. J Infect Chemother. 2024 Jan 30:S1341-321X(24)00027-8. doi: 10.1016/j.jiac.2024.01.017. Epub ahead of print. PMID: 38301745. 2: Nojima H, Shimizu H, Murakami T, Yamazaki M, Yamazaki K, Suzuki S, Shuto K, Kosugi C, Usui A, Koda K. Successful hepatic resection for invasive Klebsiella pneumoniae large multiloculated liver abscesses with percutaneous drainage failure: A case report. Front Med (Lausanne). 2023 Jan 6;9:1092879. doi: 10.3389/fmed.2022.1092879. PMID: 36687430; PMCID: PMC9852881. 3: Higashionna T, Ushio S, Esumi S, Murakawa K, Kitamura Y, Sendo T. Retrospective Cohort Study of Clinical Efficacy and Safety of Cefozopran for Treating Febrile Neutropenia during Chemotherapy in Patients with Lung Cancer. Acta Med Okayama. 2022 Apr;76(2):167-172. doi: 10.18926/AMO/63410. PMID: 35503444. 4: Kento F, Naoya I. Dark Urine in a Dialysis Patient Treated for a Bloodstream Infection. Kidney360. 2022 Feb 11;3(3):582-583. doi: 10.34067/KID.0007232021. PMID: 35582182; PMCID: PMC9034821. 5: Asai Y, Yamamoto T, Abe Y. Evaluation of the Expression Profile of Antibiotic-Induced Thrombocytopenia Using the Japanese Adverse Drug Event Report Database. Int J Toxicol. 2021 Dec;40(6):542-550. doi: 10.1177/10915818211048151. Epub 2021 Oct 18. PMID: 34658275. 6: Takeuchi N, Ohkusu M, Hishiki H, Fujii K, Hotta M, Murata S, Ishiwada N. First report on multidrug-resistant non-encapsulated Streptococcus pneumoniae isolated from a patient with pneumonia. J Infect Chemother. 2020 Jul;26(7):749-751. doi: 10.1016/j.jiac.2020.02.009. Epub 2020 May 12. PMID: 32409019. 7: Imashioya T, Kodama Y, Ooka T, Nakagawa S, Nishikawa T, Tanabe T, Okamoto Y, Imuta N, Kirishima M, Tanimoto A, Koriyama T, Nishi J, Kawano Y. Liver abscess due to Sterigmatomyces halophilus in a boy with acute lymphoblastic leukemia. J Infect Chemother. 2019 Dec;25(12):1047-1049. doi: 10.1016/j.jiac.2019.05.021. Epub 2019 Jun 10. PMID: 31196773. 8: Yamamoto T, Satoi S, Fujii T, Yamada S, Yanagimoto H, Yamaki S, Takami H, Hirooka S, Kosaka H, Kotsuka M, Miyara T, Kodera Y. Dual-center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage. Ann Gastroenterol Surg. 2018 Sep 17;2(6):442-450. doi: 10.1002/ags3.12209. PMID: 30460348; PMCID: PMC6236101. 9: Nishida S, Ono Y. Comparative analysis of the pathogenicity between multidrug-resistant Acinetobacter baumannii clinical isolates: isolation of highly pathogenic multidrug-resistant A. baumannii and experimental therapeutics with fourth-generation cephalosporin cefozopran. Infect Drug Resist. 2018 Oct 10;11:1715-1722. doi: 10.2147/IDR.S166154. PMID: 30349328; PMCID: PMC6188165. 10: Suzuki J, Sasahara T, Toshima M, Morisawa Y. Peripherally inserted central catheter-related bloodstream infection due to Tsukamurella pulmonis: a case report and literature review. BMC Infect Dis. 2017 Oct 11;17(1):677. doi: 10.1186/s12879-017-2796-8. PMID: 29020942; PMCID: PMC5637316. 11: Yasu T, Imai Y, Ohno N, Uchimaru K, Kurokawa Y, Tojo A. Hypersensitivity reaction to β-lactam antibiotics in patients with adult T-cell leukemia/lymphoma treated with mogamulizumab
. Int J Clin Pharmacol Ther. 2017 Oct;55(10):807-810. doi: 10.5414/CP203066. PMID: 28793956. 12: Mukoyama N, Nakashima M, Miyamura K, Yoshimi A, Noda Y, Mori K. Retrospective survey and evaluation of first-line antibiotics for chemotherapy- induced febrile neutropenia in patients with acute myeloid leukemia. Nagoya J Med Sci. 2017 Feb;79(1):17-26. doi: 10.18999/nagjms.79.1.17. PMID: 28303057; PMCID: PMC5346616. 13: Oie S, Mochizuki K, Ishida K, Nakayama A, Ohkusu K. Case of late-onset bleb associated endophthalmitis caused by Rothia mucilaginosa. J Infect Chemother. 2016 Sep;22(9):645-7. doi: 10.1016/j.jiac.2016.02.007. Epub 2016 Apr 11. PMID: 27008920. 14: Srinivas NR. Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion. Xenobiotica. 2016 Sep;46(9):784-92. doi: 10.3109/00498254.2015.1121554. Epub 2015 Dec 29. PMID: 26711252. 15: Negishi T, Matsumoto T, Saito S, Kasuga E, Horiuchi K, Natori T, Takehara K, Sugano M, Honda T. Catheter-Related Bacteremia Due to Gordonia sputi in a Patient with Acute Lymphocytic Leukemia: a Case Report. Jpn J Infect Dis. 2016 Jul 22;69(4):342-3. doi: 10.7883/yoken.JJID.2015.487. Epub 2016 Feb 19. PMID: 26902218. 16: Fukuda S, Komatsu M, Nakamura T, Jikimoto T, Nishio H, Yamasaki K, Satoh K, Toda H, Orita T, Sueyoshi N, Kita M, Nishi I, Akagi M, Higuchi T, Kofuku T, Nakai I, Ono T, Kida K, Ohama M, Watari H, Shimura S, Niki M, Kuchibiro T, Wada Y. [The annual changes in antimicrobial susceptibility test results of Pseudomonas aeruginosa isolates from the Kinki district]. Jpn J Antibiot. 2016 Apr;69(2):101-10. Japanese. PMID: 27544978. 17: Zalewski P, Skibiński R, Paczkowska M, Garbacki P, Talaczyńska A, Cielecka- Piontek J, Jelińska A. Stability of cefozopran hydrochloride in aqueous solutions. Drug Dev Ind Pharm. 2016;42(4):572-7. doi: 10.3109/03639045.2015.1054834. Epub 2015 Jun 16. PMID: 26079426. 18: Zalewski P, Skibiński R, Talaczyńska A, Paczkowska M, Garbacki P, Cielecka- Piontek J. Stability studies of cefoselis sulfate in the solid state. J Pharm Biomed Anal. 2015 Oct 10;114:222-6. doi: 10.1016/j.jpba.2015.05.033. Epub 2015 Jun 1. PMID: 26073113. 19: Murata S, Mushino T, Hosoi H, Kuriyama K, Kurimoto M, Watanuki J, Nishikawa A, Sonoki T, Nakakuma H, Hanaoka N. Real-time monitoring of antimicrobial use density to reduce antimicrobial resistance through the promotion of antimicrobial heterogeneity in a haematology/oncology unit. J Antimicrob Chemother. 2015 Sep;70(9):2661-4. doi: 10.1093/jac/dkv151. Epub 2015 Jun 12. PMID: 26071518. 20: Zalewski P, Garbacki P, Cielecka-Piontek J, Bednarek-Rajewska K, Krause A. DEVELOPMENT AND VALIDATION OF THE STABILITY-INDICATING LC-UV METHOD FOR DETERMINATION OF CEFOZOPRAN HYDROCHLORIDE. Acta Pol Pharm. 2015 May- Jun;72(3):423-7. PMID: 26642650.